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Mitochondrial spongiotic brain disease: astrocytic stress
and harmful rapamycin and ketosis effect
Olesia Ignatenko1 , Joni Nikkanen2 , Alexander Kononov3 , Nicola Zamboni4, Gulayse Ince-Dunn1 ,
Anu Suomalainen1,5,6
Mitochondrial DNA (mtDNA) depletion syndrome (MDS) is a group
of severe, tissue-specific diseases of childhood with unknown
pathogenesis. Brain-specific MDS manifests as devastating spongi-
otic encephalopathy with no curative therapy. Here, we report cell
type–specific stress responses and effects of rapamycin treat-
ment and ketogenic diet (KD) in mice with spongiotic encepha-
lopathy mimicking human MDS, as these interventions were
reported to improve some mitochondrial disease signs or symptoms.
These mice with astrocyte-specific knockout of Twnk gene encoding
replicative mtDNA helicase Twinkle (TwKOastro) show wide-spread
cell-autonomous astrocyte activation and mitochondrial integrated
stress response (ISRmt) induction with major metabolic remod-
eling of the brain. Mice with neuronal-specific TwKO show no
ISRmt. Both KD and rapamycin lead to rapid deterioration and
weight loss of TwKOastro and premature trial termination. Al-
though rapamycin had no robust effects on TwKOastro brain pa-
thology, KD exacerbated spongiosis, gliosis, and ISRmt. Our
evidence emphasizes that mitochondrial disease treatments and
stress responses are tissue- and disease specific. Furthermore,
rapamycin and KD are deleterious in MDS-linked spongiotic
encephalopathy, pointing to a crucial role of diet andmetabolism
for mitochondrial disease progression.
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Introduction
Mitochondrial dysfunction is emerging as a common contributor to
different degenerative disorders, including neurodegeneration
(Gorman et al, 2016). However, the mechanisms of how mito-
chondria, the cellular centers of energy metabolism, cause an
exceptional variability of non-overlapping diseases remain poorly
understood. The tissue specificity is rarely explained by variable
expression patterns of mitochondrial proteins, implying that tis-
sues and/or cell types vary in their physiological sensitivity to
mitochondrial insults. The disease group lacks curative treatment
options.
Mitochondrial DNA (mtDNA) depletion syndrome (MDS) is an
excellent example of tissue-specific mitochondrial diseases, mani-
festing either in the brain, liver, or muscle (Suomalainen & Isohanni,
2010). The causative genes affect nucleotide metabolism or mtDNA
maintenance and cause mtDNA loss (Suomalainen & Isohanni,
2010). In the brain, MDS manifests typically as severe epileptic
encephalopathy, with cortical laminar necrosis and/or spongiotic
encephalopathy (Alpers-Huttenlocher disease; encephalopathic
MDS) (Naviaux & Nguyen, 2004). One of the causes of brain-specific
MDS are defects of Twinkle, the replicative helicase and copy
number regulator of mtDNA (Tyynismaa et al, 2004; Nikali et al, 2005;
Hakonen et al, 2008; Ylikallio et al, 2010). Deficiency of functional
Twinkle causesmtDNA loss and a consequential loss ofmitochondrial
RNAs and the core subunits of the mitochondrial respiratory chain
complexes I, III, IV and V (Milenkovic et al, 2013; Ignatenko et al, 2018).
The molecular mechanisms of Twinkle-linked MDS have remained to
be discovered. Previously, we inactivated Twinkle postnatally in mice,
in either neurons (TwKOneuro) or astrocytes (TwKOastro) (Ignatenko
et al, 2018). The TwKOneuromice toleratedmtDNAdepletion until 7.5–9.5
mo of age without symptoms, and then developed acute, rapidly fatal
neurodegeneration. Interestingly, TwKOastro mice had a very dif-
ferent disease course. They developed an early-onset neurological
disease and progressive spongiotic encephalopathy, with massive cell-
autonomous activation of astrocytes (from here on, called cell-
autonomous astrogliosis). Such histological findings also character-
ize brain-specific MDS in children (Alpers, 1931; Sandbank & Lerman,
1972). Classically, reactive gliosis has been attributed to astrocyte
response to neuronal pathology (Brown & Squier, 1996; Lake et al,
2015). However, the findings from TwKOneuro and TwKOastro suggest
that astrocytes are the primary affected cell type in spongiotic
pathology in MDS. The pathophysiological mechanisms underlying
astrocytic reactivity upon mitochondrial dysfunction remain unex-
plored; however, reactive astrocytes contribute to manifestation of
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other neurodegenerative pathologies (Anderson et al, 2016; Liddelow
et al, 2017; Yun et al, 2018; Hartmann et al, 2019).
Disease-related stress responses to mitochondrial dysfunction
are starting to be elucidated. “Mitochondrial integrated stress re-
sponse” (ISRmt), with a specific transcriptional response led by ATF3-5
transcription factors, andmajor remodeling of whole-cellular anabolic
biosynthesis reactions, is induced by mtDNA expression defects or
mitochondrial uncoupling in the skeletal muscle and/or heart
(Tyynismaa et al, 2010; Ost et al, 2015; Bao et al, 2016; Nikkanen et al,
2016; Kühl et al, 2017; Restelli et al, 2018; Forsström et al, 2019; Murru
et al, 2019). ISRmt includes an early-stage induction of mitochondrial
folate cycle (methylenetetrahydrofolate dehydrogenase 2; MTHFD2),
fibroblast growth factor 21 (FGF21) and growth/differentiation factor
15 (GDF15), and a second-stage response of serine biosynthesis,
transsulfuration pathway, with both autocrine and endocrine meta-
bolic signaling roles of FGF21 (Forsström et al, 2019). The altered
metabolite homeostasis leads to imbalanced nucleotide pools and
increased levels of serine and glycine (Nikkanen et al, 2016; Forsström
et al, 2019; Murru et al, 2019). The mammalian target of rapamycin
(mTOR) complex 1 (mTORC1), a nutrient-sensor and amaster regulator
of cell growth and metabolism, is an upstream controller of ISRmt in
the heart and muscle (Nikkanen et al, 2016; Khan et al, 2017). Mouse
and human studies suggest specificity of the stress responses to the
type ofmitochondrial dysfunction or affected cell type (Lehtonen et al,
2016; Khan et al, 2017; Forsström et al, 2019; Murru et al, 2019). However,
their relevance to brain diseases remains insufficiently understood.
Rapamycin treatment, inhibiting mTORC1, rescued ISRmt induction
and ameliorated pathological hallmarks in the heart and muscle of
mitochondrial myopathy mice (Khan et al, 2017). Rapamycin has also
been reported to improve disease signs in other mouse models with
mitochondrial dysfunctions, including deficiency of respiratory chain
complex I (Johnson et al, 2013, 2015; Felici et al, 2017), mitochondrial
nucleotide salvage (Siegmund et al, 2017), or muscle complex IV (Civiletto
et al, 2018). However, rapamycin enhanced disease progression in
mice with coenzyme Q deficiency (Barriocanal-Casado et al, 2019),
indicating that not all metabolic defects may benefit from rapa-
mycin. Because of mostly encouraging results, especially in mito-
chondrial respiratory enzyme defects, rapamycin patient trials have
been initiated in children with mitochondrial encephalopathies
(https://clinicaltrials.gov/ct2/show/NCT03747328).
Dietary treatments have been proposed to ameliorate mito-
chondrial disease symptoms. Ketogenic diet (KD) has an anti-
epileptic effect and is administered on an elective basis to pa-
tients who manifest with drug-resistant epilepsy, including those
with mitochondrial disease (Wexler et al, 1997; Kang et al, 2007; Joshi
et al, 2009). Cell culture studies suggested that ketone-based
nutrition promotes selection against mtDNA deletions (Santra et
al, 2004). In mice with mitochondrial myopathy and hepatopathy,
KD promoted mitochondrial biogenesis and function (Ahola-Erkkilä
et al, 2010; Purhonen et al, 2017). However, in human patients with
mitochondrial myopathy and mtDNA deletions, KD induced se-
lective damage of the most affected muscle fibers, with moderate
long-term improvement of muscle function (Ahola et al, 2016).
These findings indicate that diet composition has a major effect for
mitochondrial muscle and liver disease progression.
Here, we report that mtDNA loss in mice activates cell-specific
stress responses in mice with either neuronal or astrocytic TwKO.
Furthermore, we explored the efficacy of rapamycin treatment and
KD for MDS-related spongiotic encephalopathy. Both interventions
led to premature cessation of the treatment trial because of ag-
gravation of disease signs. Our results highlight that mitochondrial
dysfunction in different tissues and cell types causes different
physiological and treatment responses and emphasize the need of
disease-specific treatments based on knowledge of their molecular
pathophysiology.
Results
Metabolic response to the loss of mtDNA helicase Twinkle in the
mouse brain
Twinkle depletion sequentially leads to mtDNA depletion, loss of
mtDNA gene expression, and respiratory chain dysfunction (sum-
marized in Fig 1A). MtDNA depletion in neurons causes a late-onset
cell death at preterminal stage of 7.5 mo (Ignatenko et al, 2018).
mtDNA depletion in astrocytes leads to their cell-autonomous ac-
tivation, but does not affect the number of astrocytes (Ignatenko
et al, 2018). MtDNA loss is more prominent in TwKOneuro brain than in
TwKOastro when compared to control mice (Fig S1B), replicating our
previous findings. (Ignatenko et al, 2018). TwKOneuro, however, appear
healthy, whereas TwKOastro mice progressively lose weight starting
from 2 to 3 mo of age reaching humane end point (HEP) by the age of
5–6 mo, defined as preterminal stage (Fig S1A), as we also have
reported previously (Ignatenko et al, 2018).
To understand the molecular underpinnings of the cell-specific
responses to mitochondrial dysfunction, we investigated gene ex-
pression and metabolic changes in TwKOastro and TwKOneuro mice
(Ignatenko et al, 2018). First, we asked whether ISRmt, previously
characterized in the skeletalmuscle in Twinklemutantmice (Nikkanen
et al, 2016; Khan et al, 2017; Forsström et al, 2019), is also induced in the
brain. In 5.5-mo-old TwKOastro mice, we observed an induction of the
activating transcription factors (Atf3 and Atf5), serine biosynthesis
enzymes (Phgdh and Psat1), mitochondrial folate cycle (Mthfd2), and
transsulfuration enzymes (CTH and CBS), as well as the metabolic
hormone Gdf15 (Fig 1B–D). Fgf21 expression was not detectable.
Neuronal knockout of Twinkle, however, activated none of the tested
ISRmt-related genes except for Atf3, neither at the preterminal nor
young age (7.5 and 3.5 mo, respectively) (Figs 1B–D and S1C).
Next, we evaluated whether ISRmt-linked metabolic remodeling
occurred in TwKOastro and TwKOneuro mice. Increased serine and
glycine levels are typical for ISRmt as a consequence of de novo
serine biosynthesis induction (Bao et al, 2016; Nikkanen et al, 2016).
Furthermore, altered levels of other proteinogenic amino acids
were also linked to mitochondrial dysfunction (Birsoy et al, 2015;
Nikkanen et al, 2016; Kühl et al, 2017). Our metabolomics analyses
showed a 4.5- and 3.6-fold increase of serine and glycine in
TwKOastro (Figs 1E, S1D, and Supplemental Data 1), correlating with
an induction of de novo serine biosynthesis enzymes Psat1 and
Phgdh (Fig 1B). Interestingly, these findings were not present in
TwKOneuro (Figs 1B and E, S1D and E, and Supplemental Data 2). Both
models displayed reduced aspartate and increased proline levels
(Fig 1E). Several purine precursors or degradation products, also a
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Figure 1. ISRmt is induced in the brain in response to loss of mtDNA helicase Twinkle in astrocytes.
(A) Top: schematic ofmolecular events upon Twnk knockout. Bottom:mousemodels used in the study (Ignatenkoet al, 2018). (B)mRNAexpression of ISRmt genesmeasured by
RT-quantitative PCR. TwKOastro n = 8 and their controls n = 6–7; TwKOneuro n = 8–9 and their controls n = 11. (C) Immunoblot analysis of transsulfuration pathway enzymes, CTH and
CBS. n = 6 per group. (D)GFD15mRNA expressionmeasured by RT-quantitative PCR, A.U.; “1” indicates detectable expression, N.D. indicates no detectable expression. TwKOastro n =
8 and their controls n = 7, TwKOneuro n = 5, and their controls n = 5. (E) Amino acids,metabolomics. TwKOastro n = 8 and their controls n = 8, TwKOneuro n = 5, and their controls n =
6. Multiplicity corrected P-values are shown, calculated using the Benjamini–Hochberg procedure. (F) Immunoblot analysis of S6 and phospho-S6. n = 6 per group. (G) ISRmt is
induced in TwKOastro brain, schematic representation. Ctr, control mice. For all immunoblots, densitometric quantification of signals is plotted and band intensities are
normalized to total protein on the membrane. (B, C, F) P-values are shown, calculated using unpaired two-tailed parametric t test. For all graphs, FC is a fold change ratio,
relative to corresponding Ctr mice. For all box and whiskers plots, the box extends from the 25th to 75th percentiles; whiskers show all points minimum to maximum; symbols
indicate biological replicates. Results of statistical testing can be found in Table S4 and Supplemental Data 1 and 2.
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part of ISRmt-related metabolic remodeling (Nikkanen et al, 2016),
were increased in TwKOastro but not in TwKOneuro, and uracil, a
pyrimidinemetabolite, was increased in TwKOastro (Fig S1F). mTORC1
activation is an integral component of ISRmt in mtDNAmaintenance
defects in the muscle, showing activated phosphorylation of S6, a
ribosomal protein and a target of mTORC1 (Khan et al, 2017). In
TwKOastro brains, however, the total S6 amount and p-S6 were
remarkably decreased (Fig 1F), suggesting that mTORC1 was not an
upstream regulator of ISRmt in TwKOastro.
These results indicate that astrocytes activate a robust ISRmt as a
response to TwKO, both on a transcriptional and metabolic level,
but lacking an induction of mTORC1 or Fgf21 (Fig 1G). A similar insult
in TwKOneuro did not, however, induce ISRmt. The evidence high-
lights cell type specificity of the response in the brain, indicating
that metabolic stress in astrocytes activates ISRmt.
Rapamycin does not rescue brain pathology of TwKOastro mice
To directly test the role of mTORC1 in spongiotic encephalopathy
progression, we explored the effects of mTORC1 inhibitor rapamycin
in TwKOastro mice. We intraperitoneally injected 8 mg/kg/day of
rapamycin (Rapa) or vehicle (Veh) into TwKOastro mice, starting at the
asymptomatic age of 1.5 mo (Fig 2A). After only 2 wk of treatment, the
rapamycin-injected TwKOastro mice started to lose weight reaching
a HEP at 2.3 mo of age, when the experiment was terminated (Fig 2B).
The baseline mTORC1 activity (S6 phosphorylation) was decreased
in the brains of all rapamycin-treated animals, indicating rapa-
mycin access to the brain (Fig 2C). However, genotype-dependent
differences were not present (Fig 2C), supporting the previous data
that mTORC1 was not part of ISRmt in TwKOastro.
At 2.3 mo of age, TwKOastro mice show sparsely located holes in
the brain parenchyma, colocalizing with GFAP-positive activated
astrocytes (Ignatenko et al, 2018). The progression of spongiosis and
reactive gliosis were unaffected by rapamycin (Fig 2D), indicating
that mTORC1 activation is not contributing to astrocyte activation or
progression of themitochondrial spongiotic encephalopathy. At the
early age of 2.3 mo, TwKOastro did not yet show detectable changes
in the components of ISRmt, with or without rapamycin treatment
(Fig S2A and B). The brain metabolome of TwKOastro did not show a
global shift as a consequence of rapamycin treatment, and no
evident genotype- or treatment-related clusters were observed (Fig
S2C and Supplemental Data 2). However, elevated serine and
glycine levels seen in untreated TwKOastro mice were normalized by
rapamycin treatment, and the drug also increased methionine
levels in TwKOastro mice (Fig S2D). Furthermore, rapamycin in-
creased glutamine levels of both wild-type and TwKOastro mice
suggesting its increased production or decreased usage (Fig S2D).
Several metabolites showed changes attributable to the genotype
(Fig 2E, genotype panel). Rapamycin administration affected the
levels of more than 20 metabolites, signifying the overall role of
mTORC1 signaling in the brain (Fig 2E, treatment panel). Most of
those metabolites were affected similarly in Ctr and TwKOastro mice,
implying a similar status of mTORC1 activity in both genotypes. Only
three metabolites showed changes attributable to an interaction of
the treatment and genotype (Fig 2E, interaction panel). Saccha-
ropine was the most significantly increased metabolite in TwKOastro
and was partially rescued by rapamycin treatment (Fig 2F). In
mammals, saccharopine is a degradation product of the es-
sential amino acid lysine, and conversion of lysine to saccha-
ropine occurs in the mitochondria (Higashino et al, 1965, 1967).
Several lipid metabolites were slightly decreased in TwKOastro
brain and were not affected by rapamycin treatment (Fig 2E,
genotype panel; Fig 2F).
Finally, we tested whether rapamycin has an effect in TwKOastro
brain when started after disease manifestation, at a moderately
advanced pathological stage (3 mo, Fig 2G). TwKOastro did not tol-
erate the treatment well, and their body weight started to decline at
already the third day of treatment (Fig 2H). HEP was reached 2 wk
after treatment initiation, and the experiment was terminated.
However, we found no changes in the brain pathology between the
vehicle- and rapamycin-treated mice (Fig 2I). Taken together,
rapamycin was not improving the spongiotic pathology and caused
rapid deterioration of the mice. The data propose that rapamycin is
not a promising treatment strategy for spongiotic encephalopathy
because of mtDNA depletion.
KD worsens the brain pathology of TwKOastro
KDs are administered to patients with drug-resistant epilepsy,
including patients with mitochondrial diseases, but knowledge of
the mechanisms or usefulness in different epileptic states remains
limited. We administered KD or regular chow diet for TwKOastro mice
after weaning, before disease manifestation (Fig 3A). KD increased
blood β-hydroxybutyrate levels, indicating efficient ketosis (Fig 3B).
Weight progression slowed down both in Ctr and TwKOastro mice (Fig
3C), and HEP of TwKOastro body weight loss was reached after 9.5 wk
of treatment, requiring termination of the mice (Fig 3C). KD re-
markably aggravated brain pathology of TwKOastro mice. The
spongiosis and gliosis weremore severe than those inmice fed with
regular chow diet (Fig 3D). Of ISRmt transcripts, Atf3 and Atf5 showed
further induction (Fig S3A), and transsulfuration enzymes levels
were increased in KD-fed TwKOastro mice (Fig 3E). Gdf15 mRNA was
detectable in all TwKOastro mice but not in the Ctr mice, with high
variation in KD-fed TwKOastro mice (Fig S3B).
Analysis of brain metabolome revealed major metabolic
reprogramming of TwKOastro brain at 3.2 mo of age (Fig S3C and
Supplemental Data 2). 128 out of 382 detected metabolites showed
changes attributable to the genotype (Figs 3F and S3D), whereas
only seven were changed at 2.3 mo of age (Fig 2E). KD modified the
metabolome of both TwKOastro and Ctr brain (Fig S3D, treatment
panel). In TwKOastro, the level of saccharopine, the most signifi-
cantly changed metabolite at the early disease stage in TwKOastro
(Fig 2F), was further increased in KD-fed TwKOastro (Fig 3G). KD also
boosted levels of serine and glycine in TwKOastro, indicating further
up-regulation of ISRmt in treated mice, despite the fact that de novo
serine synthesis enzyme expression levels were not detectably
induced at this age (Figs 3G and S3A). KD increased methionine
levels in Ctr but not in TwKOastro mice (Fig S3E). Levels of other
proteogenic amino acids were mostly unchanged in TwKOastro mice
(Fig S3E). Aspartate, produced in the mitochondria, was decreased
by KD in TwKOastro, potentially reducing overall translation (Fig 3G).
ATP, ADP, UDP, and FAD declined after KD in TwKOastro but not in Ctr
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Figure 2. Rapamycin does not prevent or rescue brain pathology of TwKOastro.
(A, B, C, D, E, F, G, H, I) Rapamycin treatment started at presymptomatic (A, B, C, D, E, F) and at a moderately advanced (G, H, I) phenotype stage. (A) Schematic of
presymptomatic rapamycin treatment. Daily i.p. injections of rapamycin or vehicle were initiated at 1.5 mo and were continued until humane end point in body weight loss
was reached (2.3 mo, arrow). Green area shows treatment period and pink area represents symptom progression in untreated TwKOastro mice. (B) Body weight progression
upon rapamycin treatment initiated at the presymptomatic stage. Weight change is shown as a fold change (FC) relative to the body weight at treatment initiation (zero
time point). n = 9 per group. Mean with SD is shown. (C) Immunoblot analysis of total S6 and phospho-S6 proteins. Ctr Veh n = 4, Ctr Rapa n = 4, TwKOastro Rapa n = 4,
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(Fig 3F), indicating an imbalance of nucleotide metabolism and
high-energy phosphate donors in diseased mice.
Altogether, our evidence indicates a remarkable effect of diet
and nutrient composition to the progression of mitochondrial
spongiotic encephalopathy, with deleterious consequences of both
rapamycin and KD.
Discussion
How different diseases and treatments affect metabolism in dis-
tinct tissues and cell types is a central question concerning
mechanisms of tissue specificity and treatment effects. The topic is
especially important for mitochondrial diseases that show an ex-
ceptional variability of manifestations, despite the primary origin
being in one organelle. Here, we demonstrate that astrocytes and
neurons respond differently to metabolic stress caused by TwKO
and mtDNA loss. Astrocyte-specific TwKO leads to a robust mito-
chondrial integrated stress response, associated with cell-autonomous
activation of the astrocytes, whereas in neurons, a similar stress causes
few signs of ISRmt. Furthermore, we show that metabolic modifier in-
terventions, rapamycin andKD, are deleterious formicemanifestingwith
mitochondrial spongiotic encephalopathy related to mtDNA depletion
syndrome. Our results highlight the context-dependence of stress and
treatment responses, even when different cell types encounter similar
stresses.
Mitochondrial transcriptome and proteome in astrocytes and
neurons differ (Eraso-Pichot et al, 2018; Fecher et al, 2019), indi-
cating specialization of mitochondrial functions to distinct cell
types of the brain. We show here thatmtDNA depletion in astrocytes
causes ISRmt that closely resembles the response reported in the
skeletal muscle and heart with mtDNA expression insult (Nikkanen
et al, 2016; Khan et al, 2017; Kühl et al, 2017; Forsström et al, 2019) or
mitochondrial uncoupling (Ost et al, 2015). Astrocytic but not
neuronal mtDNA depletion induced de novo serine biosynthesis
and transsulfuration pathway enzyme expression. Previous reports
found that in a healthy brain, the expression of these enzymes is
enriched in astrocytes compared with other brain cell types, which
possibly also explains the differential regulation of these pathways
uponmtDNA loss (Zhang et al, 2014; Chai et al, 2017; Diaz-Castro et al,
2019). The signals for the induction are unknown, but could involve
amino acids, metabolites, ATP, redox-status, gasotransmitter hydrogen
sulfide, and/or glutathione synthesis. In the Twinkle-linked mtDNA
expression defect manifesting as mitochondrial myopathy, and in
cultured cancer cells, a similar ISRmt response drove glucose carbon
flux to glutathione synthesis (Locasale, 2013; Nikkanen et al, 2016) and
to NADH production (Yang et al, 2020). Which of the pleiotropic glucose
carbon fates are crucial for astrocytes with MDS remains unknown.
Specific changes in amino acid metabolism were found in
TwKOastro mice. Serine and glycine amounts were increased, con-
sistent with induced serine biosynthesis. Proline amount was in-
creased both in TwKOneuro and TwKOastro mice. Proline is oxidized by
proline dehydrogenase, which is enriched in astrocyte mitochon-
dria (Zhang et al, 2014), and contributes to NADP/NADPH recycling
between mitochondria and the cytosol, as well as ATP production
upon nutrient stress. Proline metabolism was suggested to be part
of ISRmt in different mtDNA expression defects in the heart (Kühl
et al, 2017), thereby indicating this pathway to be widely remodeled
upon mitochondrial dysfunction in different cell types. Aspartate
level was reduced in TwKOastro and was also previously reported to
be a marker of mitochondrial dysfunction in cancer cells (Birsoy
et al, 2015). Overall, our evidence highlights the central role of
astrocyte mitochondria in amino acid metabolism in the brain.
Saccharopine is an intermediate of lysine metabolism in
mammalian tissues (Hallen et al, 2013), including cultured human
astrocytes and neuronal progenitors (Crowther et al, 2019) and was
one of the most significantly up-regulated metabolites in TwKOastro
brain. Lysine degradation functions as an antioxidative pathway in
yeast (Olin-Sandoval et al, 2019); however, saccharopine accumu-
lation causes swelling of mitochondria in Caenorhabditis elegans
and mice (Zhou et al, 2019). Our data point to saccharopine to be a
novel, early marker of mitochondrial dysfunction in the brain, the
contributions of which to pathogenesis remain to be studied.
mTORC1 is a major regulator of amino acid metabolism and has
also been reported to control the key components of ISRmt
(transsulfuration, mitochondrial folate cycle, nucleotide synthesis,
and serine biosynthesis) in human cancer cells (Ben-Sahra et al,
2016) and in the heart and muscle in mitochondrial myopathy mice
(Khan et al, 2017). However, we found no signs of mTORC1 activation
in the brain of TwKOastro, which otherwise robustly up-regulated
TwKOastro Veh n = 5. 2× is a Ctr Veh sample, with a twofold amount of protein loaded on the lane compared with other samples. (D) Brain pathology, rapamycin treatment.
Left: Representative cortical sections show spongiotic encephalopathy. Hematoxylin and eosin staining of TwKOastro treated with vehicle or rapamycin. Arrows show
sponge-like holes typical for spongiotic encephalopathy. Quantification below: counts of holes per field of view, n = 7 mice per group, two sections per mouse, three fields
of view per section. Counts from the fields of view of one mouse are plotted with the same symbol. Scale bars, 50 μm. Right: Astrocyte activation. Glial fibrillary acidic
protein (GFAP), immunofluorescent detection, cortex, representative of n = 7 mice per group, two sections per mouse. Below: mRNA expression of GFAP and vimentin
(reactive gliosis markers) measured by RT-quantitative PCR. Ctr Veh n = 8, Ctr Rapa n = 8, TwKOastro Veh n = 7–8, TwKOastro Rapa n = 7. (E) Metabolomics analysis. All
metabolites with P-value < 0.01 in any of the two-way ANOVA tests (interaction, genotype, and treatment) are plotted. Z-scores are calculated from intensity values. Note
that metabolite is plotted more than once if it passes selection criteria in more than one test. n = 6 per group. Full data set is shown in Fig S2C. (F) Metabolomics, full data
set is shown in Fig S2C. n = 6 per group. Multiplicity corrected P-values are shown, calculated using the Benjamini–Hochberg procedure. (G, H, I) Rapamycin treatment
started at a moderately advanced phenotype stage. (G) Schematic of the rapamycin treatment at a moderately advanced disease stage of TwKOastro mice. Daily i.p.
injections of rapamycin or vehicle were started at a moderately advanced phenotype stage (3 mo) and were continued until humane end point in body weight loss was
reached (3.5 mo, arrow). Green area shows treatment period and the pink area represents symptom progression in untreated TwKOastro mice. (H) Body weight progression
upon rapamycin treatment initiated at a moderately advanced disease stage. Ctr Veh n = 3, Ctr Rapa n = 5, TwKOastro Veh n = 7, TwKOastro Rapa n = 8. Weight change is
shown as an FC relative to the body weight at treatment initiation (zero time point). Mean with SD is shown. (I)Quantification of spongiotic encephalopathy. Counts of holes
per field of view in brain sections stained with hematoxylin and eosin, 1–2 sections per mouse, three fields of view per section. Counts from fields of view of the same
mouse are plotted with the same symbol. TwKOastro Veh n = 6, TwKOastro Rapa n = 8. Ctr, control mice; Veh, vehicle-treated mice; Rapa, rapamycin-treated mice. (C, D)
P-values are shown, calculated using two-way ANOVA followed by Tukey correction for multiple comparisons. For all graphs, FC is a fold change ratio, relative to
corresponding Ctr mice. For all box and whiskers plots, the box extends from the 25th to 75th percentiles; whiskers show all points minimum to maximum; symbols
indicate biological replicates. Results of statistical testing can be found in Table S4 and Supplemental Data 2.
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Figure 3. Ketogenic diet accelerates brain pathology of TwKOastro.
Ketogenic diet started upon weaning of the mice. (A) Schematic representation of the ketogenic diet experiment. Ketogenic or chow diet was administered to the mice
upon weaning. Experiment was continued until humane end point body weight loss of TwKOastro was reached (3.2 mo, arrow). Green area shows a treatment period and
pink area represents a symptom progression in untreated TwKOastro mice. (B) Blood β-hydroxybutyrate levels 8 wk after start of the experiment. Ctr Chow n = 10, Ctr Keto
n = 7, TwKOastro Chow n = 9, TwKOastro Keto n = 8. (C) Body weight progression. Ctr Chow n = 12, Ctr Keto n = 8, TwKOastro Chow n = 16, TwKOastro Keto n = 14. Weight change is
shown as fold change (FC) relative to the zero time point. Mean with SD is shown. (D) Brain pathology, ketogenic diet. Left: Spongiotic encephalopathy. Representative
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ISRmt components. Rapamycin treatment did not affect brain pa-
thology of TwKOastro but caused accelerated body weight loss
leading to a premature cessation of the experiment. The harmful
effect was not expected, as previous reports suggested beneficial
effects of rapamycin on different mousemodels withmitochondrial
dysfunction: in NDUFS4-KO (Johnson et al, 2013, 2015; Felici et al,
2017), thymidine kinase-2 knock-in (Siegmund et al, 2017), and
muscle-specific COX15-KO (complex IV assembly deficiency)
(Civiletto et al, 2018) mice. Recently, rapamycin failed to rescue the
brain pathology of mice with coenzyme Q deficiency, characterized
by spongiotic encephalopathy and astrogliosis, similar to TwKOastro
mice (Garcı́a-Corzo et al, 2013; Barriocanal-Casado et al, 2019). In
chow-fed TwKOastro, the levels of ubiquinone-1 and ubiquinone-2
aredecreasedat the age of 3.2mo, suggesting a secondary coenzymeQ
deficiency (Supplemental Data 2). Whether similar metabolic changes
in astrocytes underlie spongiosis and negative rapamycin effect in CoQ
deficiency and TwKOastro remains to be studied. These results indicate
that the effect of rapamycin depends on the underlying primary defect
and may be deleterious in mitochondrial spongiotic encephalopathy.
Rapamycin has profound effects on organismalmetabolism in general,
which may also contribute to the worsening of the phenotype, even in
an encephalopathic model.
KD was also poorly tolerated by TwKOastro, and different from
rapamycin, it accelerated the brain pathology progression. Astro-
cytes ensure nutrient uptake from the blood flow and are believed
to survive rather severe mitochondrial dysfunction because of their
capacity to up-regulate glycolysis (Supplie et al, 2017). KD, however,
minimizes glucose availability for glycolytic ATP production. Despite
this knowledge, KD has been used to treat epilepsy in mitochondrial
diseases (Wexler et al, 1997; Kang et al, 2007; Joshi et al, 2009). Our
findings present a proof-of-principle that KD worsens spongiotic
encephalopathy caused by mitochondrial dysfunction in astrocytes.
In conclusion, the exceptional heterogeneity and tissue specificity
of different mitochondrial diseases indicate that mitochondrial
functions are cell type specific. Therefore, also the pathophysio-
logical changes may drastically vary in different diseases, and
require specific treatments. Promising results of interventions, such
as rapamycin and KD in some mitochondrial diseases, are not
automatically generalizable to the whole disease group. Our
preclinical data indicate deleterious effects of rapamycin and KD
in brain-related MDS, with rapid deterioration of general condition
and/or brain pathology of the mice. Therefore, our evidence does not
support the use of these intervention strategies for mitochondrial
spongiotic encephalopathy or epilepsy linked with mtDNA depletion.
Our results indicate that metabolic modifier therapies and diets are
potent modifiers of disease progression.
Limitations of the study
Usage of genetically modified mouse models with cell type–specific
gene knockouts provided important insights into the physiology of
tissues in normal and pathological conditions. However, comparing
different Cre-induced knockouts with each other is limited by the
absence of strict temporal control of the effect of knockout, that is,
different rates of loss of the targeted product in different cells or
tissues, as well as differently tolerated thresholds of such loss.
Most, if not all, genes showing exclusive or highly enriched ex-
pression in astrocytes in brain tissue are also expressed at some
level by peripheral organs. GFAP73.12-Cre used to generate
TwKOastro is expressed by subpopulations of neurons in the mouse
cortex, and by specific peripheral tissues (Bush et al, 1998; Smith
et al, 2019). Such expression was unlikely to affect the findings, as
TwKOneuro showed no responses even in the terminal stage, as
these were found in the TwKOastro soon after symptom manifes-
tation, and the spongiotic encephalopathy observed in TwKOastro is
a very distinct finding. Future studies are needed to study the
relevance of our findings for human MDS manifesting with mor-
phologically similar spongiotic pathology.
Materials and Methods
Animal studies
Animal experiments were approved by The National Animal Ex-
periment Review Board and Regional State Administrative Agency
for Southern Finland, following the European Union Directive. Mice
were maintained in a vivarium with 12-h light:dark cycle at 22°C.
Mice were fed with Altromin 1324 diet and water ad libitum, unless
otherwise specified. C57Bl/6OlaHsd or mixed genetic background
mice were used (mixed background originates from mT/mG re-
porter mice). TwKOastro and TwKOneuro models are derived from
breeding mice carrying loxP sites in Twnk gene (Twloxp/loxp) to
(Gfap73.12-Cre Twloxp/loxp) or (CamKII-Cre Twloxp/loxp), respectively.
Gfap73.12-Cre, CamKII-Cre, and mT/mG were originally received
from The Jackson Laboratory and maintained in the local mouse
facility (Stock No: 005359, 012886, 00757). Twloxp/loxp mice carry
Y508C mutation in the targeted Twnk gene (Nikkanen et al, 2016).
cortical sections, hematoxylin and eosin staining of TwKOastro fed with chow or ketogenic diet. Arrows show sponge-like holes typical for spongiotic encephalopathy.
Quantification below: counts of holes per field of view, TwKOastro Chow n = 6, TwKOastro Keto = 8, one to two sections per mouse, three fields of view per section. Counts from
the fields of view of onemouse are plotted with the same symbol. Scale bars, 50 μm. Right: Astrogliosis. GFAP, immunofluorescent detection, cortex, representative of n = 8
mice per group, two sections per mouse. Below: mRNA expression of GFAP and vimentin (astrocyte activation markers) measured using RT-quantitative PCR. Ctr Chow
n = 7, Ctr Keto n = 8, TwKOastro Chow n = 8, TwKOastro Keto n = 8. (E) Immunoblot analysis of transsulfuration pathway enzymes CTH and CBS. Densitometry of Western blot
signals: a protein signal normalized to the total protein in the membrane. n = 5 per group. 2× is a Ctr Chow sample with a twofold amount of protein loaded on the lane,
compared with other samples. (F)Metabolomics analysis. Metabolites with P-value < 0.01 in the two-way ANOVA interaction tests, and a cluster of metabolites with
P-value < 0.01 in the two-way ANOVA genotypes tests are plotted (see selection of the cluster in Fig S3D). Z-scores are calculated from intensity values. Note thatmetabolite
is plottedmore than once if it passes selection criteria in more than one test. Ctr Chow, Ctr Keto n = 6; TwKOastro Chow, TwKOastro Keto n = 5. Full data set is shown in Fig S3C.
(G) Metabolomics, full data set is shown in Fig S3C. Ctr Chow n = 6, Ctr Keto n = 6, TwKOastro Chow n = 5, TwKOastro Keto n = 5. Multiplicity corrected P-values are shown,
calculated using the Benjamini–Hochberg procedure. Ctr, control mice; Chow, mice fed with chow diet; Keto, mice fed with ketogenic diet. For all graphs, FC is a fold change
ratio, relative to corresponding Ctr mice. For all box and whiskers plots, the box extends from the 25th to 75th percentiles; whiskers show all points minimum to maximum;
symbols indicate biological replicates. (C, D, E) P-values are shown, calculated using two-way ANOVA followed by Tukey correction for multiple comparisons. Results of
statistical testing can be found in Table S4 and Supplemental Data 2.
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Twloxp/loxp and Twloxp/null littermates were used as controls, which
are asymptomatic and indistinguishable from wild-type mice. The
preterminal stage is defined upon reaching HEP as follows: 7.5-mo-
old TwKOneuro (before or upon severe manifestation preceding
death of otherwise asymptomatic mice) and 5.5-mo-old TwKOastro
(due to body weight loss, otherwise lethal at 7–8 mo as described
previously) (Ignatenko et al, 2018). Exact ages and sexes of mice
used in the study can be found in Table S1.
Rapamycin treatment
Rapamycin (#R-5000; LC Laboratories) was dissolved in DMSO to 100
mg/ml, then further diluted in 5% PEG-400/5% Tween 20 to a final
concentration of 1.6 mg/ml, sterile filtered, and stored at −80°C.
Mice were weighed individually, and 8 mg/kg of body weight of
rapamycin was injected daily intraperitoneally at the indicated
dosage, previously shown to be effective in the brain (Johnson et al,
2013), as in Khan et al (2017). Control mice were injected with the
same volume of diluent without rapamycin.
KD
Mice were administered upon weaning with Teklad Custom Diet
TD.170470 containing short- and medium-chain fatty acids; with
coconut oil, milk fat, and soybean oil as fat sources. 90.5% kcal is
derived from fat, 9.2% from protein, and 0.3% from carbohydrates.
The ratio of fat to protein + carbohydrate is ~4.25. KD was admin-
istered on a petri dish to the bottom of the cage and changed every
3–4 d. Control mice were administered with an Altromin 1324 chow
diet. Mice which failed to accept the diet and lost body weight upon
initiating the diet were terminated and not included in the study.
β-hydroxybutyrate levels were measured as follows: food was re-
moved from the cage for 4 h, and β-hydroxybutyrate was measured
from a tail vein drop of blood with Freestyle Precision b-Ketone,
Abbott.
Tissue collection
Mice were euthanized with CO2, blood was collected by cardiac
puncture, and mice were decapitated. Brain was removed from the
skull and placed into an acrylic brain slicer. Sagittal cut along the
midline was made, and one 3-mm hemisphere slice was collected
into 4% PFA in PBS fixative for histological experiments, post-fixed,
dehydrated, and paraffin-embedded. The second hemisphere was
dissected, and pieces of cortex were snap-frozen in liquid nitrogen.
RT quantitative PCR
15–30 mg of snap-frozen mouse brain cortex was lysed in QIAzol
lysis reagent (QIAGEN) in soft tissue homogenizing tubes with
ceramic beads (Precellys) using Precellys 24 homogenizer (Pre-
cellys). Total RNA was extracted using the RNeasy kit (QIAGEN). RNA
concentration was measured using the NanoDrop1000 Spectro-
photometer. Maxima first-strand cDNA synthesis kit with dsDNAse
(Thermo Fisher Scientific) was used to eliminate genomic DNA and
to generate cDNA from 600 to 1,500 ng of RNA. cDNA was diluted to
1/20-1/50, and 1 μl of diluted cDNA was used for RT-quantitative
PCR reactions performed with IQ SybrGreen kit (Bio-Rad) or Sen-
siFast SYBR kit (Bioline). Oligonucleotides were designed to amplify
70–150-bp-long product and to be separated by at least one intron
of the corresponding genomic DNA of a minimum 1,000 bp length
(whenever possible) using NCBI primer BLAST software (Ye et al,
2012). Oligonucleotides with 85–105% efficiency which amplifies one
product of expected length were selected. All oligonucleotide se-
quences can be found in Table S2. The expression of the genes of
interest was normalized to hydroxymethylbilane synthase (HMBS)
expression.
MtDNA copy number analysis
15–30 mg of snap-frozen mouse brain was lysed in TNES buffer with
Proteinase K at 55°C in a water bath overnight. DNA was extracted
with phenol–chloroform extraction followed by ethanol and am-
monium acetate precipitation. Pellet was washed with ethanol,
dried, and resuspended in Tris–HCl. Analysis of mtDNA was per-
formed by quantitative PCR and normalized to a nuclear gene;
primer sequences can be found in Table S2.
Western blotting
15–30 mg of snap-frozen mouse brain was solubilized in a buffer
containing 50 mM Tris–HCL, pH 7.5, 150 mM NaCl, 1% Triton X-100,
protease inhibitor cocktail (Roche), and phosphatase inhibitor
cocktail (Thermo Fisher Scientific). Protein concentrations were
measured by the Bradford Assay (Bio-Rad), and the concentration
was adjusted to 1 μg/ul in Laemmli sample buffer. Equal amounts
(typically, 7.5 μg) of proteins were loaded on Criterion or mini-
PROTEAN TGX Stain-Free 4–20% precast gels (Bio-Rad), separated
by Tris-glycine SDS–PAGE and transferred to PVDF membranes
using Trans-Blot Turbo Transfer System (Bio-Rad). BlueStar Plus
pre-stained protein marker was used to estimate the molecular
weight of the proteins. Stain-free membrane images upon transfer
completion were used for the normalization of protein chemilu-
minescent signal. Membranes were blocked in Tris-buffered saline
with 0.1% Tween (TBST) with 4% milk for 1 h at room temperature.
Primary antibodies were incubated overnight at +4°C, diluted in
1.5% BSA/TBST or 4% milk/TBST, and detected the following day
with secondary HRP-conjugated antibodies using ECL (Bio-Rad).
Unsaturated images were collected with a ChemiDoc detection
system. Images for the main figures were cropped in Adobe In
Design or Adobe Photoshop, and linear adjustments of brightness
and contrast were applied equally across the entire image. Original
photographs of Western blotmembranes can be found in Fig S4. List
of used antibodies can be found in Table S3. Densitometry analysis
was performed in ImageLab software (Bio-Rad).
Histology
Histological and immunofluorescent assays were carried on 7–10-
μm deparaffinized sagittal sections.
Hematoxylin and eosin
Brain sections were stained with hematoxylin and eosin. 1–2 brain
sections per mouse were imaged and digitalized with Pannoramic
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Digital Slide Scanner (3DHISTECH). Three snapshots of cortical area
per section were acquired in CaseViewer software by an investi-
gator blind to the genotypes and treatments of the mice.
Spongiotic pathology
Spongiotic pathology was quantified from hematoxylin and eosin
stain images acquired by an investigator blind to genotypes and
treatments. Counting was performed in Fiji software by marking
round-shaped holes corresponding to spongiotic pathology by an
investigator blind to the treatments of the mice.
Immunofluorescence
Antigen retrieval by heating in 10 mM citric acid was performed on
brain sections. Samples were blocked by incubation in the following
blocking solution: 10% horse serum and 0.1% Triton X-100 in PBS at
room temperature. Consequently, sections were incubated overnight
at +4°Cwith primary antibodies diluted in blocking solution. Next day,
the sections were incubated with secondary antibodies conjugated
with Alexa Fluor fluorescent probes (Thermo Fisher Scientific) diluted
in blocking solution and mounted with DAPI-containing mounting
medium (Vectashield). Imageswere acquiredwith a Zeiss Axio Imager
epifluorescent microscope, and only linear adjustments were ap-
plied. A list of used antibodies can be found in Table S3.
Metabolomics
Targeted metabolomics
Targeted metabolomics was performed using Waters Acquity ultra-
performance liquid chromatography and triple-quadrupole mass
spectrometry analysis in FIMM (Institute for Molecular Medicine Fin-
land) as in Nikkanen et al (2016), Khan et al (2017) and Forsström et al
(2019). The polar metabolome was extracted from frozen 20 mgmouse
muscle and lysed with ceramic beads (Precellys) containing labeled
internal standardmix and extraction solvent. The exact procedure and
its validation are described inNandania et al (2018). Quantificationwas
performed by internal standards and external calibration curves.
Untargeted metabolomics
20–30 mg of snap-frozen mouse brain cortex was homogenized in
70% ethanol cold extraction solvent (handled in ethanol cold bath
with dry ice, approximately −40°C) with ceramic beads using a
Precellys 24 homogenizer (Precellys). The polar metabolome was
extracted with 70% ethanol in water (prewarmed) at 75°C for 1 min.
The clear extracts were analyzed by flow injection analysis on an
Agilent 6550 QTOF instrument (Fuhrer et al, 2011) in negative mode.
Putative annotations were made searching against the Human
Metabolome Database (version 3.6) using accurate mass (tolerance
0.001m/z) and isotopic patterns. While this approach is sufficient to
assign molecular formulas in most cases, it does not allow dis-
tinguishing between isomers. For simplicity, only one name is re-
ported in the heat map, but the full annotation is provided in
Supplemental Data 2.
Statistical analysis
Statistical analysis of data presented in the figures is reported in
the Table S4, and was performed using Prism 8 and Excel
(Microsoft); graphs were made with Prism 8 software. A comparison
of two groups (Figs 1 and S1) was performed using unpaired two-
tailed parametric t test. Analysis of treatment experiments (Figs 2, 3,
S2, and S3) was performed using two-way ANOVA and Tukey cor-
rection for multiple comparisons (Prism 8). Statistical analysis of
metabolomics data can be found in Supplemental Data 1 and 2 and
was performed in R using two-tailed parametric t test to calculate the
P-value followed by false discovery rate–based methods of P-value
calculation: p.adjusted value was calculated using the Benjamini–
Hochberg procedure (Benjamini & Hochberg, 1995); qvalue was
calculated using Storey and Tibshirani (2003) and Storey et al (2020).
Heatmaps were generated using R (Gu et al, 2016), and clustering was
supervised by genotypes and treatments. To find metabolites
identified in both targeted and untargeted metabolomics data sets,
HMDB identifiers were used (Figs 1E and S1E).
Data Availability
Full metabolomics data are available as supplementary data sets.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
202000797.
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Bullejos-Peregrı́n J, López A, Escames G, Enrı́quez JA, et al (2013)
Dysfunctional Coq9 protein causes predominant encephalomyopathy
associated with CoQ deficiency. Hum Mol Genet 22: 1233–1248.
doi:10.1093/hmg/dds530
Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R,
Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM (2016)
Mitochondrial diseases. Nat Rev Dis Primers 2: 16080. doi:10.1038/
nrdp.2016.80
Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and
correlations in multidimensional genomic data. Bioinformatics 32:
2847–2849. doi:10.1093/bioinformatics/btw313
Hakonen AH, Goffart S, Marjavaara S, Paetau A, Cooper H, Mattila K, Lampinen
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